Atopic Dermatitis Outcome Measures

  • Cathy Yunjia Zhao
  • Dedee F. MurrellEmail author
Living reference work entry


The validation and standardization of outcome measures for atopic dermatitis (AD) have advanced significantly in the last decade, predominantly led by the Harmonizing Outcome Measures for Eczema (HOME) initiative. Clinical signs, symptoms, quality of life, and long-term control have been defined by the HOME group as the core outcome domains to be used as primary or secondary endpoints for atopic dermatitis trials. The Eczema Area and Severity Index (EASI) score was chosen as the core measure for the clinical signs domain, among at least 13 other measures of clinical signs. The Patient-Oriented Eczema Measure (POEM) score was chosen the core measure for the symptoms domain, among at least 12 other measures of symptoms. Various outcome measures for the QoL domain have also been investigated, with the Quality of Life Index for Atopic Dermatitis (QoLIAD) and the Dermatological Life Quality Index (DLQI) being two of the more preferred measures for eczema clinical trials, although the better of the two is yet to be decided by consensus. HOME is also making progress toward defining the core outcome measure for the long-term control domain, with future consensus meetings planned.


Harmonizing Outcome Measures for Eczema (HOME) Eczema Area and Severity Index (EASI) Patient-Oriented Eczema Measure (POEM) Quality of Life Index for Atopic Dermatitis (QoLIAD) Dermatological Life Quality Index (DLQI) 


  1. Alam MN, Munia TT, Tavakolian K, Vasefi F, MacKinnon N, Fazel-Rezai R. Automatic detection and severity measurement of eczema using image processing. In: Conference proceedings: Annual International conference of the ieee engineering in medicine and biology society IEEE engineering in medicine and biology society annual conference 2016;2016:1365–8.Google Scholar
  2. Augustin M, Lange S, Wenninger K, Seidenglanz K, Amon U, Zschocke I. Validation of a comprehensive Freiburg Life Quality Assessment (FLQA) core questionnaire and development of a threshold system. Eur J Dermatol. 2004;14:107–13.PubMedGoogle Scholar
  3. Bahmer FA. ADASI score: atopic dermatitis area and severity index. Acta Derm Venereol Suppl. 1992;176:32–3.Google Scholar
  4. Barbarot S, Rogers NK, Abuabara K, et al. Strategies used for measuring long-term control in atopic dermatitis trials: a systematic review. J Am Acad Dermatol. 2016;75:1038–44.CrossRefGoogle Scholar
  5. Barbier N, Paul C, Luger T, et al. Validation of the Eczema Area and Severity Index for atopic dermatitis in a cohort of 1550 patients from the pimecrolimus cream 1% randomized controlled clinical trials programme. Br J Dermatol. 2004;150:96–102.CrossRefGoogle Scholar
  6. Berth-Jones J. Six area, six sign atopic dermatitis (SASSAD) severity score: a simple system for monitoring disease activity in atopic dermatitis. Br J Dermatol. 1996;135(Suppl 48):25–30.CrossRefGoogle Scholar
  7. Bozek A, Reich A. Assessment of intra- and inter-rater reliability of three methods for measuring atopic dermatitis severity: EASI, objective SCORAD, and IGA. Dermatology. 2017;233:16–22.CrossRefGoogle Scholar
  8. Carel K, Bratton DL, Miyazawa N, et al. The Atopic Dermatitis Quickscore (ADQ): validation of a new parent-administered atopic dermatitis scoring tool. Ann Allergy Asthma Immunol. 2008;101:500–7.CrossRefGoogle Scholar
  9. Chalmers JR, Schmitt J, Apfelbacher C, et al. Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME). Br J Dermatol. 2014;171(6):1318–25.CrossRefGoogle Scholar
  10. Chalmers JR, Simpson E, Apfelbacher CJ, et al. Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative). Br J Dermatol. 2016;175:69–79.CrossRefGoogle Scholar
  11. Charman C, Chambers C, Williams H. Measuring atopic dermatitis severity in randomized controlled clinical trials: what exactly are we measuring? J Invest Dermatol. 2003;120:932–41.CrossRefGoogle Scholar
  12. Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol. 2013;169:1326–32.CrossRefGoogle Scholar
  13. Charman CR, Venn AJ, Williams HC. Reliability testing of the Six Area, Six Sign Atopic Dermatitis severity score. Br J Dermatol. 2002;146:1057–60.CrossRefGoogle Scholar
  14. Charman CR, Venn AJ, Williams HC. The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients’ perspective. Arch Dermatol. 2004;140:1513–9.CrossRefGoogle Scholar
  15. Charman D, Varigos G, Horne DJ, Oberklaid F. The development of a practical and reliable assessment measure for atopic dermatitis (ADAM). J Outcome Meas. 1999;3:21–34.PubMedGoogle Scholar
  16. Chopra R, Vakharia PP, Sacotte R, et al. Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis. Br J Dermatol. 2017;177:1316–21.CrossRefGoogle Scholar
  17. Chren MM, Lasek RJ, Flocke SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997;133:1433–40.CrossRefGoogle Scholar
  18. Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996;107:707–13.CrossRefGoogle Scholar
  19. Costa C, Rilliet A, Nicolet M, Saurat JH. Scoring atopic dermatitis: the simpler the better? Acta Derm Venereol. 1989;69:41–5.PubMedGoogle Scholar
  20. Coutanceau C, Stalder JF. Analysis of correlations between patient-oriented SCORAD (PO-SCORAD) and other assessment scores of atopic dermatitis severity and quality of life. Dermatology. 2014;229:248–55.CrossRefGoogle Scholar
  21. Darsow U, Scharein E, Simon D, Walter G, Bromm B, Ring J. New aspects of itch pathophysiology: component analysis of atopic itch using the ‘Eppendorf Itch Questionnaire’. Int Arch Allergy Immunol. 2001;124:326–31.CrossRefGoogle Scholar
  22. Dawn A, Papoiu AD, Chan YH, Rapp SR, Rassette N, Yosipovitch G. Itch characteristics in atopic dermatitis: results of a web-based questionnaire. Br J Dermatol. 2009;160:642–4.CrossRefGoogle Scholar
  23. Deckers IA, McLean S, Linssen S, Mommers M, van Schayck CP, Sheikh A. Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies. PLoS One. 2012;7:e39803.CrossRefGoogle Scholar
  24. Eichenfield LF, Lucky AW, Boguniewicz M, et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol. 2002;46:495–504.CrossRefGoogle Scholar
  25. Emerson RM, Charman CR, Williams HC. The Nottingham Eczema Severity Score: preliminary refinement of the Rajka and Langeland grading. Br J Dermatol. 2000;142:288–97.CrossRefGoogle Scholar
  26. Esamai F, Ayaya S, Nyandiko W. Prevalence of asthma, allergic rhinitis and dermatitis in primary school children in Uasin Gishu district. Kenya East Afr Med J. 2002;79:514–8.PubMedGoogle Scholar
  27. Evers AW, Duller P, van de Kerkhof PC, et al. The Impact of Chronic Skin Disease on Daily Life (ISDL): a generic and dermatology-specific health instrument. Br J Dermatol. 2008;158:101–8.PubMedGoogle Scholar
  28. Felce D, Perry J. Quality of life: its definition and measurement. Res Dev Disabil. 1995;16:51–74.CrossRefGoogle Scholar
  29. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19:210–6.CrossRefGoogle Scholar
  30. Furue M, Ebata T, Ikoma A, et al. Verbalizing extremes of the visual analogue scale for pruritus: a consensus statement. Acta Derm Venereol. 2013;93:214–5.CrossRefGoogle Scholar
  31. Gerbens LA, Prinsen CA, Chalmers JR, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2016;72(1):146–63.CrossRefGoogle Scholar
  32. Gerbens LA, Prinsen CA, Chalmers JR, et al. Evaluation of the measurement properties of symptom measurement instruments for atopic eczema: a systematic review. Allergy. 2017;72:146–63.CrossRefGoogle Scholar
  33. Haest C, Casaer MP, Daems A, et al. Measurement of itching: validation of the Leuven Itch Scale. Burns. 2011;37:939–50.CrossRefGoogle Scholar
  34. Hanifin J, Rajka G. Diagnostic features of atopic eczema. Acta Derm Venereol Suppl. 1980;92:44–7.Google Scholar
  35. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol. 2001;10:11–8.CrossRefGoogle Scholar
  36. Heinl D, Prinsen CA, Deckert S, et al. Measurement properties of adult quality-of-life measurement instruments for eczema: a systematic review. Allergy. 2016;71:358–70.CrossRefGoogle Scholar
  37. Housman TS, Patel MJ, Camacho F, Feldman SR, Fleischer AB Jr, Balkrishnan R. Use of the Self-Administered Eczema Area and Severity Index by parent caregivers: results of a validation study. Br J Dermatol. 2002;147:1192–8.CrossRefGoogle Scholar
  38. Jenkins HH, Spencer ED, Weissgerber AJ, Osborne LA, Pellegrini JE. Correlating an 11-point verbal numeric rating scale to a 4-point verbal rating scale in the measurement of pruritus. J Perianesth Nurs. 2009;24:152–5.CrossRefGoogle Scholar
  39. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10–9.CrossRefGoogle Scholar
  40. Langan SM, Stuart B, Bradshaw L, Schmitt J, Williams HC, Thomas KS. Measuring long-term disease control in patients with atopic dermatitis: a validation study of well-controlled weeks. J Allergy Clin Immunol. 2017;140:1580–6.CrossRefGoogle Scholar
  41. Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity Index score tells us about the severity of atopic dermatitis: an interpretability study. Br J Dermatol. 2015;172:1353–7.CrossRefGoogle Scholar
  42. Majeski CJ, Johnson JA, Davison SN, Lauzon CJ. Itch Severity Scale: a self-report instrument for the measurement of pruritus severity. Br J Dermatol. 2007;156:667–73.CrossRefGoogle Scholar
  43. Melzack R. The McGill pain questionnaire: from description to measurement. Anesthesiology. 2005;103:199–202.CrossRefGoogle Scholar
  44. Minutes of the HOME III Meeting. 2013. Accessed 22 Dec 2017.Google Scholar
  45. Minutes of the HOME IV Meeting. 2015. Accessed 26 Dec 2017.Google Scholar
  46. Mokkink L, Terwee C, Patrick D, Alonso J, Stratford P, Knol D, et al. COSMIN checklist manual. Amsterdam: VU University Medical Center; 2009.Google Scholar
  47. Murao Y, Mae H, Konishi T, Gao X, Tanizawa T. Semiquantitative scoring in children under treatment for atopic dermatitis. Pediatr Int. 2004;46:330–6.CrossRefGoogle Scholar
  48. Oh JW, Pyun BY, Choung JT, et al. Epidemiological change of atopic dermatitis and food allergy in school-aged children in Korea between 1995 and 2000. J Korean Med Sci. 2004;19:716–23.CrossRefGoogle Scholar
  49. Oranje AP, Stalder JF, Taieb A, Tasset C, de Longueville M. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. ETAC Study Group. Early Treatment of the Atopic Child. Pediatr Allergy Immunol. 1997;8:28–34.CrossRefGoogle Scholar
  50. Reich A, Heisig M, Phan NQ, et al. Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol. 2012;92:497–501.CrossRefGoogle Scholar
  51. Robertson CF, Roberts MF, Kappers JH. Asthma prevalence in Melbourne schoolchildren: have we reached the peak? Med J Aust. 2004;180:273–6.PubMedGoogle Scholar
  52. Rullo VE, Segato A, Kirsh A, Sole D. Severity scoring of atopic dermatitis: a comparison of two scoring systems. Allergol Immunopathol. 2008;36:205–11.CrossRefGoogle Scholar
  53. Schmitt J, Langan S, Deckert S, et al. Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation. J Allergy Clin Immunol. 2013;132:1337–47.CrossRefGoogle Scholar
  54. Schmitt J, Langan S, Stamm T, Williams HC. Core outcome domains for controlled trials and clinical recordkeeping in eczema: international multiperspective Delphi consensus process. J Invest Dermatol. 2011;131:623–30.CrossRefGoogle Scholar
  55. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting. Allergy. 2012;67:1111–7.CrossRefGoogle Scholar
  56. Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134:800–7.CrossRefGoogle Scholar
  57. Schmitt J, Williams H. Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany. Br J Dermatol. 2010;163:1166–8.CrossRefGoogle Scholar
  58. Schram ME, Spuls PI, Leeflang MM, Lindeboom R, Bos JD, Schmitt J. EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference. Allergy. 2012;67:99–106.CrossRefGoogle Scholar
  59. SCORAD. Foundation for Atopic Dermatitis, 2017. Accessed 23 Dec 2017.
  60. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children’s Health. J Invest Dermatol. 2011;131:67–73.CrossRefGoogle Scholar
  61. Silny W, Czarnecka-Operacz M, Silny P. The new scoring system for evaluation of skin inflammation extent and severity in patients with atopic dermatitis. Acta Dermatovenerol Croat. 2005;13:219–24.PubMedGoogle Scholar
  62. Simpson CR, Newton J, Hippisley-Cox J, Sheikh A. Trends in the epidemiology and prescribing of medication for eczema in England. J R Soc Med. 2009;102:108–17.CrossRefGoogle Scholar
  63. Sprikkelman AB, Tupker RA, Burgerhof H, et al. Severity scoring of atopic dermatitis: a comparison of three scoring systems. Allergy. 1997;52:944–9.CrossRefGoogle Scholar
  64. Stalder JF, Barbarot S, Wollenberg A, et al. Patient-Oriented SCORAD (PO-SCORAD): a new self-assessment scale in atopic dermatitis validated in Europe. Allergy. 2011;66:1114–21.CrossRefGoogle Scholar
  65. Stalder JF, Taïeb A. Severity scoring of atopic dermatitis: the SCORAD index. Consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1993;186:23–31.CrossRefGoogle Scholar
  66. Sugarman JL, Fluhr JW, Fowler AJ, Bruckner T, Diepgen TL, Williams ML. The objective severity assessment of atopic dermatitis score: an objective measure using permeability barrier function and stratum corneum hydration with computer-assisted estimates for extent of disease. Arch Dermatol. 2003;139:1417–22.CrossRefGoogle Scholar
  67. Sugiura H, Umemoto N, Deguchi H, et al. Prevalence of childhood and adolescent atopic dermatitis in a Japanese population: comparison with the disease frequency examined 20 years ago. Acta Derm Venereol. 1998;78:293–4.CrossRefGoogle Scholar
  68. Tofte S, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin JM. Eczema area and severity index (EASI): a new tool to evaluate atopic dermatitis. J Eur Acad Dermatol Venereol. 1998;11:S197.CrossRefGoogle Scholar
  69. Vakharia PP, Chopra R, Sacotte R, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925–930.CrossRefGoogle Scholar
  70. van Joost T, Heule F, Korstanje M, van den Broek MJ, Stenveld HJ, van Vloten WA. Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study. Br J Dermatol. 1994;130:634–40.CrossRefGoogle Scholar
  71. van Velsen SG, Knol MJ, Haeck IM, Bruijnzeel-Koomen CA, Pasmans SG. The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity. Pediatr Dermatol. 2010;27:470–5.CrossRefGoogle Scholar
  72. Verwimp JJ, Bindels JG, Barents M, Heymans HS. Symptomatology and growth in infants with cow’s milk protein intolerance using two different whey-protein hydrolysate based formulas in a Primary Health Care setting. Eur J Clin Nutr. 1995;49(Suppl 1):S39–48.PubMedGoogle Scholar
  73. von Kobyletzki LB, Thomas KS, Schmitt J, et al. What factors are important to patients when assessing treatment response: an international cross-sectional survey. Acta Derm Venereol. 2017;97:86–90.CrossRefGoogle Scholar
  74. Vourc’h-Jourdain M, Barbarot S, Taieb A, et al. Patient-oriented SCORAD: a self-assessment score in atopic dermatitis. A preliminary feasibility study. Dermatology. 2009;218:246–51.CrossRefGoogle Scholar
  75. Whalley D, McKenna SP, Dewar AL, et al. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol. 2004;150:274–83.CrossRefGoogle Scholar
  76. Williams HC, Burney PG, Hay RJ, et al. The U.K. Working Party’s Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994;131:383–96.CrossRefGoogle Scholar
  77. Wolkerstorfer A, de Waard van der Spek FB, Glazenburg EJ, Mulder PG, Oranje AP. Scoring the severity of atopic dermatitis: three item severity score as a rough system for daily practice and as a pre-screening tool for studies. Acta Derm Venereol. 1999;79:356–9.CrossRefGoogle Scholar
  78. Wu D, Huang C, Mo X, et al. Development and initial validation of a Traditional Chinese Medicine symptom-specific outcome measure: a Zheng-related atopic dermatitis symptom questionnaire (ZRADSQ). Health Qual Life Outcomes. 2013;11:212.CrossRefGoogle Scholar
  79. Zar HJ, Ehrlich RI, Workman L, Weinberg EG. The changing prevalence of asthma, allergic rhinitis and atopic eczema in African adolescents from 1995 to 2002. Pediatric allergy and immunology: official publication of the. Eur Soc Pediatr Allergy Immunol. 2007;18:560–5.CrossRefGoogle Scholar
  80. Zhao CY, Hao EY, Oh DD, et al. A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients. Br J Dermatol. 2017;176:985–92.CrossRefGoogle Scholar
  81. Zhao CY, Tran AQ, Lazo-Dizon JP, et al. A pilot comparison study of four clinician-rated atopic dermatitis severity scales. Br J Dermatol. 2015;173:488–97.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of DermatologySt George HospitalSydneyAustralia
  2. 2.Sydney Medical SchoolUniversity of SydneySydneyAustralia
  3. 3.Faculty of MedicineUniversity of New South WalesSydneyAustralia

Personalised recommendations